Topsale Products,High Quality Topsale Products,Topsale Products Details, CN Xi'an Healthway Biotech Co.,Ltd , https://www.xahealthway.com
The author of the "China Pharmaceutical Manufacturing Industry Safety Assessment Report" (2009-2010), the head of the medical industry security early warning project team and the director of the comprehensive department of the China Medical Insurance Chamber of Commerce, Xu Ming, in an interview with reporters, believes that the Chinese pharmaceutical manufacturing industry Competitiveness is increasing year by year, but the industrial security situation still faces many challenges. The Chinese pharmaceutical industry needs to take advantage of the current pharmaceutical industry's annual growth rate of more than 20%, catch up, play the advantage of latecomer, and rapidly improve the international competitiveness of the industry. To a higher level.
At the same time, Xu Ming also stressed that the improvement of the industrial competitiveness of China's pharmaceutical manufacturing industry must be based on the improvement of corporate competitiveness. It requires a group of enterprises with strength, vision and daring to open up the market in order to make the entire pharmaceutical industry faster. Step to the international market.
The reporter learned that the industrial safety of China's pharmaceutical manufacturing industry is an important part of China's pharmaceutical economy. Especially after China's accession to the WTO, industrial safety reflects the Chinese pharmaceutical industry's resistance to external interference or threats, and continues to achieve sustainable development, to a large extent. It reflects the dominant position and competitiveness of China's pharmaceutical industry, and is also a concentrated reflection of the comprehensive quality of the pharmaceutical industry at different stages of development.
However, with the continuous deepening of participation in international competition, the situation facing the safety of China's pharmaceutical industry is becoming increasingly severe. So, how to build an effective evaluation system to track, analyze and provide important decision-making basis in real time has become a top priority.
The pharmaceutical manufacturing industry is a sunrise industry that integrates capital, technology and knowledge-intensive, and is also a strategic industry involving the national economy and people's livelihood. After decades of development, China's pharmaceutical manufacturing industry has made great achievements and become a major pharmaceutical country in the world. Among them, the production capacity of western medicine preparations ranks globally*, and the output of raw material medicines ranks in the world*.
However, as a big country with a population of 1.3 billion, China has also become a major market for international pharmaceutical companies to compete for in the context of the current comprehensive reform of the medical system. The game between domestic and foreign pharmaceutical companies is becoming more and more complicated. China's pharmaceutical manufacturing industry is facing multiple tasks of upgrading industrial structure, ensuring relatively stable domestic market share and opening up international markets. In view of this, it is of great practical significance to conduct empirical analysis on the pharmaceutical manufacturing industry (including western medicine preparations, western medicine raw materials, biochemical medicines and traditional Chinese medicine products).
In order to further understand the analysis results and general conclusions of the report on the competitiveness of the pharmaceutical industry, the reporter focused on the main contents and issues covered by the four major indicators involved in the report, in order to allow readers to have an overall General understanding.
"Pharmaceutical Economics": "China's pharmaceutical manufacturing industry safety assessment report" (hereinafter referred to as "report") in the industry-based indicators, industry scale, industry structure, upstream industry and other indicators have relatively high scores, but industry prices The score is only 54 points. Is this phenomenon normal in China, what is the reason? The scores of the indicators reflect the current status of the industrial base.
Xu Ming: We found from the data analysis that there are many problems in the domestic drug price generation mechanism. According to the statistics, the investigation team believes that the price of the drug in the manufacturing process is not high, the profit of the production enterprise is relatively thin, and the majority of the profit of the drug is obtained from the circulation of drugs and the terminal, including the new one to be implemented. The round of price cuts, all of which directly blame the responsibility on the head of the production company is "mistaken the board". It should be said that this phenomenon is not normal.
In contrast, most of the drugs of foreign companies have independent intellectual property rights, which can form a price monopoly. Therefore, the price of the drug is higher, most of the profits are obtained by the drug manufacturer, and the profit of the drug circulation is very thin. This is a very big contrast with the domestic.
Briefly describe the requirements of China's reverse osmosis water treatment equipment
"Currently, China's pharmaceutical manufacturing industry is in a state of basic security, but the difficulties and challenges are still grim." The 2009-2010 annual report of the "China Pharmaceutical Manufacturing Industry Safety Assessment Report" released for the first time recently reached the above conclusion, industrial safety score. For 63 points, the overall rating is "B+.